Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;23(3):928-936.
doi: 10.1016/j.jtha.2024.12.004. Epub 2024 Dec 13.

The history of women and hemophilia: a narrative review of evolving beliefs and testing practices

Affiliations
Free article
Review

The history of women and hemophilia: a narrative review of evolving beliefs and testing practices

Megan Chaigneau et al. J Thromb Haemost. 2025 Mar.
Free article

Abstract

The history of hemophilia is well documented, yet reports focus heavily on the male perspective and severe forms of the disease. Although hemophilia was initially believed to only affect men with women seen as silent carriers, it is now universally acknowledged that women and girls can also be affected. In this narrative review, we tracked the progression of beliefs about women and hemophilia as documented in the literature from pre-1800s to the present time. We present a timeline of evolving beliefs and testing practices and identified 9 distinct time periods when key shifts occurred related to various scientific discoveries. Our review highlights how women affected by hemophilia experienced complete dismissal of their health issues despite evidence of bleeding symptoms as early as the 1900s. We identified 1990 as a major timepoint for shifting beliefs when large scale acknowledgment that hemophilia also affects women is documented and systematic testing for bleeding risk is first suggested. Women evolve from being seen as unaffected genetic transmitters only, to being recognized as a population affected by hemophilia in unique ways requiring timely testing and effective treatment. Yet, despite this clear progress, recent publications continue to document many persistent issues such as delayed diagnosis, untreated symptoms, and barriers to care. Ongoing research and advocacy efforts are required to improve knowledge translation until real-world outcomes are seen in screening, diagnosis, treatment, and prevention of bleeding.

Keywords: blood coagulation disorders, inherited; genetic carrier screening; hemophilia A; hemophilia B; history of medicine; women’s health.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interests P.J. has received research funding from Bayer and consultancy with Star/Vega, Band/Guardian, Roche, and Biomarin. D.L. has received research funding from Biomarin, CSL-Behring, and Sanofi and acted in an advisory role for Biomarin, CSL-Behring, Novo Nordisk, Pfizer, and Takeda. M.S. has received research funding from Octapharma and Pfizer (to institution), and honoraria for speaking engagements from Pfizer, Octapharma, Takeda, Sobi, and Medison. All other authors have no competing interests to declare.

LinkOut - more resources